New cancer clinical trial: Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.

Published on: February 27, 2018 at 12:00PM
Condition:   Non Small Cell Lung Cancer (NSCLC)
Intervention:   Drug: Pembrolizumab
Sponsor:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Not yet recruiting
http://ift.tt/2HOX0BA